Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTOMWB)

Drug Name

BI 1206 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
B-cell lymphoma	2A86	Phase 1/2	[1]
Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[1]
leukaemia	2A60-2B33	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Immunoglobulin gamma Fc receptor IIB (FCGR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Xmab 5871	DMLIPY1	Autoimmune diabetes	5A10	Phase 2	[3]
MGD010	DMA368V	Autoimmune disease	4A40-4A45	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Immunoglobulin gamma Fc receptor IIB (FCGR2B)	TT5RWKQ	FCG2B_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02933320) BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of BioInvent.
3	CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)